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INTRODUCTION: 
CHARACTERISTICS OF ORAL DISPERSIBLE 
DELIVERY SYSTEMS
1,2 
EASY OF ADMINISTRATION: 
Oral Dispersible Delivery Systems are easy to administer and 
handle hence, leads to better patient compliance. Usually, 
elderly people experience difficulty in swallowing the 
conventional dosage forms (tablets, capsules, solutions and 
suspensions) because of tremors of extremities and dysphagia. 
Oral Dispersible tablets may offer a solution for these 
problems.
 
 
TASTE OF THE MEDICAMENT: 
As most drugs are unpalatable, mouth dissolving delivery 
systems usually contain the medicament in taste masked form. 
Delivery systems dissolve or disintegrate in patient’s mouth, 
thus releasing the active ingredients which come in contact 
with the taste buds and hence, taste masking of the drugs 
becomes critical to patient compliance.
 
 
HYGROSCOPICITY: 
Several Oral Dispersible dosage forms are hygroscopic and 
cannot maintain physical integrity under normal condition 
from humidity which calls for specialized product packaging.
 
 
FRIABILITY: 
In order to allow Oral Dispersible tablets to dissolve in the 
mouth, they are made of either very porous and soft- molded 
matrices or compressed into tablets with very low 
compression force, which makes the tablets friable and/or 
brittle which are difficult to handle, often requiring 
specialized peel-off blister packaging. 
 
MOUTH FEEL: 
Mouth feel is critical, and patients should receive a product 
that feels pleasant. Any large particles from the disintegrating 
tablet that are insoluble or slowly soluble in saliva would lead 
to an unpleasant gritty feeling. This can be overcome by 
keeping the majority of the particles below the detectable size 
limit. In some cases, certain flavours can imbibe an improved 
mouth feel perception, resulting in a product that is perceived 
as being less gritty, even if the only change is the flavour.  
Effervescence can be added to aid disintegration and improve 
mouth feel by reducing the "dryness" of a product. 
 VARIOUS TECHNOLOGIES USED IN THE 
MANUFACTURE OF ODT:  
The performance of ODT depends on the technology used in 
their manufacture. The orally disintegrating property of the 
tablet is attributable to a quick ingress of water into the tablet 
matrix, which creates porous structure and results in rapid 
disintegration. Hence, the basic approaches to develop ODT 
include maximizing the porous structure of the tablet matrix, 
incorporating the appropriate disintegrating agent & using 
highly water-soluble excipient in the formulation
24
. Following 
technologies have been used by various researchers to prepare 
ODT: -  
a) Freeze-Drying or Lyophilization  
b) Tablet Molding  
c) Sublimation  
d) Direct Compression  
e) Cotton Candy Process  
f) Mass-Extrusion  
g) Wet granulation method 
h) Spray Drying  
a) Freeze-Drying or Lyophilization
26 
Freeze drying is the process in which water is sublimed from 
the product after it is frozen. This technique creates an 
amorphous porous structure that can dissolve rapidly.  
A typical procedure involved in the manufacturing of ODT 
using this technique is mentioned here. The active drug is 
dissolved or dispersed in an aqueous solution of a 
carrier/polymer. The mixture is poured in the wells of the 
preformed blister packs. The trays holding the blister packs 
are passed through liquid nitrogen freezing tunnel to freeze 
the drug solution or dispersion. Then the frozen blister packs 
are placed in refrigerated cabinets to continue the freeze-
drying. After freeze-drying the aluminium foil backing is 
applied on a blister-sealing machine. Finally the blisters are 
packaged and shipped. 
The freeze-drying technique has demonstrated improved 
absorption and increase in bioavailability. Remon and 
Corveleyn in one of their study found maltodextrins very 
useful in preparing oral dispersible tablets by lyophilization. 
The major disadvantages of lyophilisation technique are that it 
is expensive and time consuming; Fragility makes 
conventional packaging unsuitable for these products and 
poor stability under stressed conditions.
 
ABSTRACT: 
Oral Dispersible tablets are well recognised dosage forms presented in the market. The various advantages that they offer to the patients in 
terms of massive revenues by line extension of products include a variety of advantages. The development of oral dispersible tablets has 
been formulated for pediatric, geriatric, and bed rest patients and for those people as well as patients who may not have access to 
water.several formulation provide and opportunity for product line extension especially for elderly persons will have difficulties  in taking 
conventional oral dosage forms because of hand termors and dysphasia. Basically swallowing problems also are happen in young 
individuals because of their under developed muscular and nervous systems. In some cases such as motion sickness, coughing, and an 
unavailability of water,swallowing conventional tablets may be difficult or improper.  
Key wordS: ODT, Mechanism of action, Method of preparation, Patented Technology, Super Disintegrants. 
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b) TABLET MOLDING
24,25 
The preparation of ODT using molding technology employs 
water-soluble ingredients so that the tablet dissolves 
completely and rapidly. The active ingredients in most cases 
are absorbed through the mucosal lining of the mouth. 
Molding process is of two type’s i.e. solvent method and heat 
method. Solvent method involves moistening the powder 
blend with a hydro alcoholic solvent followed by compression 
at low pressures in molded plates to form a wetted mass 
(compression molding). The solvent is than removed by air-
drying. The tablets manufactured in this manner are less 
compact than compressed tablets and posses a porous 
structure that hastens dissolution. The heat molding process 
involves preparation of a suspension that contains a drug, agar 
and sugar (e.g. Mannitol or lactose) and pouring the 
suspension in the blister packaging wells, solidifying the agar 
at the room temperature to form a jelly and drying at 30˚ 
under vacuum. The mechanical strength of molded tablets is a 
matter of great concern. Binding agents, which increase the 
mechanical strength of the tablets, need to be incorporated. 
Taste masking is an added problem to this technology. To 
overcome this, Van Scoik
 
incorporated taste masked drug 
particles. The taste masked drug particles were prepared by 
spray congealing a molten mixture of hydrogenated 
cottonseed oil, sodium carbonate, lecithin, polyethylene 
glycol, and an active ingredient into a lactose based tablet 
triturate form. Compared to the lyophilization technique, 
tablets produced by the molding technique are easier to scale 
up for industrial manufacture. Masaki uses an agar solution as 
a binding agent and a blister packaging as well as a mold to 
prepare an intrabuccally fast disintegrating tablet. 
 
c) SUBLIMATION
20,21 
The key to rapid disintegration of ODT is preparation of a 
porous structure in the tablet matrix. To generate such a 
porous matrix, volatile ingredients are incorporated in the 
formulation, that is later subjected to a process of sublimation. 
Highly volatile ingredients like ammonium bicarbonate, 
ammonium carbonate, benzoic acid, camphor, naphthalene, 
urea, urethane and phthalic anhydride may be compressed 
along with other excipients into a tablet. This volatile material 
is then removed by sublimation leaving behind a highly 
porous matrix. Tablets manufactured by this technique have 
reported to usually disintegrate in 10-20 sec. Even solvents 
like cyclohexane, benzene can be used as pore forming 
agents.  
Figure 1: Sublimation method 
Vacuum drying technique has been very often used by 
researchers to sublimate the volatile ingredients and thus 
maximize the porous structure in the tablet matrix. It is likely 
that a porous hydrophilic matrix will easily pick up the 
disintegrating medium and break quickly. 
d)  DIRECT COMPRESSION
24,25 
Direct compression represents the simplest and most cost 
effective tablet manufacturing technique. This technique can 
now be applied in the preparation of ODT because of the 
availability of improved excipients especially 
superdisintegrants & sugar based excipients. 
(a) Superdisintegrants
 
In many orally disintegrating tablet technologies based on 
direct compression, the addition of superdisintegrants 
principally affects the rate of disintegration and hence the 
dissolution. The presence of other formulation ingredients 
such as water-soluble excipients and effervescent agents 
further hastens the process of disintegration. Bi and Wantanbe 
have used microcrystalline cellulose (MCC) and low 
substituted hydroxyl propyl cellulose (HPC) to manufacture 
ODT. The ratio of MCC to HPC varied from 8:2 to 9:1. Ito 
and Sugihara
 
investigated use of agar powder as a disintegrant 
because the powder absorbs water and swells without forming 
gel at physiological temperature. Ethylpharm (France) has 
introduced a Flash- dose technology, which contains coated 
crystals and micro granules along with the disintegrant. In this 
technology, two types of granules are used; a disintegrating 
agent (e.g. modified cellulose- croscarmellose) which has a 
high swelling force, and a swelling agent (e.g. starch) which 
has a low swelling force. 
Shirwaikar and co-workers prepared Atenolol tablets by dry 
granulation method using three superdisintegrant, 
croscarmellose sodium (Ac-Di-Sol), crospovidone and 
sodium starch glycolate, and they found that Ac-Di-Sol was 
the best superdisintegrant among the three. 
(b) Sugar Based Excipients 
This is another approach to manufacture ODT by direct 
compression. The use of sugar based excipient especially 
bulking agents like dextrose, fructose, isomalt, lactilol, 
maltilol, maltose, Mannitol, sorbitol, starch hydrolysate, 
polydextrose and xylitol, which display high aqueous 
solubility and sweetness, and hence impart taste masking 
property and a pleasing mouth feel. 
ODT formulators prefer to use a directly compressible 
Mannitol, which enables the preparation of robust tablets that 
can withstand processing and transportation. Specially 
textured directly compressible, spray-dried, or granulated 
Mannitol excipient has been designed to meet these needs. 
These excipients under defined manufacturing conditions 
gives a highly porous structure and friable exterior structure 
which helps in faster disintegration of ODT. This also 
provides a satisfactory mouth feel and is suitable for use in 
preparation of harder ODT by direct compression at low 
pressure.
 
e) COTTON CANDY PROCESS
19 
The cotton candy process is also known as the “candy floss” 
process and forms the basis of the technologies such as Flash 
Dose
®
 (Fuisz Technology). An ODT is formed using a 
candyfloss or shear form matrix; the matrix is formed from 
saccharides or polysaccharides processed into amorphous 
floss by a simultaneous action of flash melting and centrifugal 
force. The matrix is then cured or partially recrystallised to 
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provide a compound with good flow properties and 
compressibility. The candyfloss can then be milled and 
blended with active ingredients and other excipient and 
subsequently compressed into ODT. However the high 
processing temperature limits the use of this technology to 
thermo stable compounds only.
 
f) MASS-EXTRUSION
19
 
This technology involves softening the active blend using the 
solvent mixture of water-soluble polyethylene glycol and 
methanol and subsequent expulsion of softened mass through 
the extruder or syringe to get a cylinder of the product into 
even segments using heated blade to form tablets. The dried 
cylinder can also be used to coat granules for bitter drugs and 
thereby achieve taste masking. 
g) WET GRANULATION METHOD
19
 
This technology involves the binding of the mixture of drug 
and suitable filler with the binder, like starch paste or PVP. 
After binding of the mass, it is dried until little moisture 
remains in the mass. Then for production of the suitable size 
granules, the mass is passed through the sieve. After that the 
size reduction, superdisintegrant is added and other remaining 
materials, like talc or magnesium stearate are added and 
mixed. This mixture is than compressed to form tablets. 
Addition of the superdisintegrant can be done either during 
granulation, intra granulation or extra granulation. Sometimes 
superdisintegrant is added partly in the formulation i.e. 50% 
amount is added during granulation and remaining amount is 
added after granulation. 
h) SPRAY DRYING
19 - 23  
Spray drying is used in pharmaceutical industries to produce 
highly porous powders. The processing solvent is evaporated 
rapidly by spray drying, which renders the product highly 
porous and thus can be used in manufacturing ODT.  
In this technique, gelatine can be used as a supporting agent 
and as a matrix, Mannitol as a bulking agent and sodium 
starch glycolate or croscarmellose or crospovidone are used as 
superdisintegrant. Tablets manufactured from the spray-dried 
powder have been reported to disintegrate in less than 20 
seconds in aqueous medium. 
Allen and Wang have reported this technique for preparing 
fast dissolving tablets. The formulation contained bulking 
agent like Mannitol and lactose, a superdisintegrant like 
sodium starch glycolate & croscarmellose sodium and acidic 
ingredient (citric acid) and/or alkaline ingredients (e.g. 
sodium bicarbonate). This spray-dried powder, which 
compressed into tablets showed rapid disintegration and 
enhanced dissolution. 
PATENTED TECHNOLOGIES FOR ORALLY 
DISINTEGRATINGTABLETS 
15-18 
1) Zydis Technology.  
2) Durasolve Technology.  
3) Orasolve Technology.  
4) Flash Dose Technology.  
5) Wow Tab Technology.  
6) Flash Tab Technology.  
7) Oraquick Technology.  
8) Quick –Dis Technology.  
9) Nanocrystal Technology.  
1) ZYDIS TECHNOLOGY: 
 Zydis, the best known of the mouth-dissolving/disintegrating 
tablet preparations, was the first marketed new technology 
tablet. A Zydis tablet is produced by lyophilizing or freeze-
drying the drug in a matrix usually consisting of gelatine. The 
product is very lightweight and fragile, and must be dispensed 
in a special blister pack. The Zydis product is made to 
dissolve on the tongue in 2 to 3 seconds. A major claim of the 
Zydis product is increased bioavailability compared to 
traditional tablets. Because of its dispersion and dissolution in 
saliva while still in the oral cavity, there can be a substantial 
amount of pre-gastric absorption from this formulation. Any 
pre-gastric absorption avoids first-pass metabolism and can be 
an advantage to drugs that undergo a great deal of hepatic 
metabolism. There are some disadvantages to the Zydis 
technology. As mentioned earlier, the Zydis formulation is 
very lightweight and fragile, and therefore should not be 
stored in backpacks or the bottom of purses. Finally, the Zydis 
formulation has poor stability at higher temperatures and 
humidity. It readily absorbs water, and is very sensitive to 
degradation at humidity greater than 65%. 
2) DURASOLV TECHNOLOGY: 
Durasolv is Cima's second-generation fast-
dissolving/disintegrating tablet formulation. DuraSolv has 
much higher mechanical strength than Orasolv due to the use 
of higher compaction pressures during tableting. DuraSolv 
product is thus produced in a faster and more cost-effective 
manner. DuraSolv is so durable that it can be packaged in 
either traditional blister packaging or vials. This technology is 
not compatible with larger doses of active ingredients, 
because the formulation is subjected to such high pressures on 
compaction. Unlike Orasolv, the structural integrity of any 
taste masking may be compromised with high drug doses. The 
drug powder coating in Durasolv may become fractured 
during compaction, exposing the bitter-tasting drug to a 
patient's taste buds. Therefore, Durasolv technology is best 
suited for formulations including relatively small doses of 
active compound. The tablets made by this technology consist 
of a drug, fillers and a lubricant and prepared by using 
conventional tableting equipment and have good rigidity. 
These can be packed into conventional packaging system like 
blisters. Due to higher force of compaction used, tablets 
prepared are rigid. 
3) ORASOLV TECHNOLOGY: 
Orasolv® is Cima’s first orally disintegrating dosage form. It 
based on direct compression of an effervescent agent and taste 
masked drug. The use of effervescence causes a tablet to 
disintegrate rapidly in less than 1 min on contact with water 
or saliva leaving coated drug powder. This technique is 
frequently used to develop over the counter formulations. 
This technology can accommodate a wide range of active 
ingredient from 1 mg to 500 mg. The effervescence occurs 
due to chemical reaction between organic acid such as citric 
acid, fumaric acid or maleic acid and a base such as sodium 
bicarbonate, potassium bicarbonate, bicarbonate, which result 
in generation of CO2 . Effervescent disintegration agents 
evolve gas by means of chemical reaction called effervescent 
couple. Carbonates such as sodium bicarbonate, sodium 
carbonate, potassium bicarbonate and potassium carbonate, 
magnesium carbonate, and acids like citric, tartaric, fumaric, 
adipic and succinic are used. Microparticles, effervescent 
agents and other ingredient such as flavours, sweeteners, 
colorants and lubricants are blended and compressed at a low 
degree of compaction. 
4) FLASH: 
The FlashDose technology utilizes a unique spinning 
mechanism to produce a floss-like crystalline structure, much 
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like cotton candy. This crystalline sugar can then incorporate 
the active drug and be compressed into a tablet. This 
procedure has been patented by Fuisz and is known as Shear 
form. The final product has a very high surface area for 
dissolution. It disperses and dissolves quickly once placed 
onto the tongue. Flash dose tablets consist of self–binding 
shear form matrix termed as “floss”. Shear form matrices are 
prepared by flash heat processing and are of two types.  
5) WOWTAB TECHNOLOGY: 
The Wowtab mouth-dissolving/disintegrating tablet 
formulation has been in the Japanese market for a number of 
years. The WOW in Wowtab signifies the tablet is to be given 
“With out Water”. The Wowtab technology utilizes sugar and 
sugar-like (e.g., mannitol) excipients. This process uses a 
combination of low mould ability saccharides (rapid 
dissolution) and high mould ability saccharide (good binding 
property).The two different types of saccharides are combined 
to obtain a tablet formulation with adequate hardness and 
mouth dissolution rate. Due to its significant hardness, the 
Wowtab formulation is a bit more stable to the environment 
than the Zydis or OraSolv. It is suitable for both conventional 
bottle and blister packaging. The Wowtab product dissolves 
quickly in 15 seconds or less. 
 
TECHNOLOGIES EMPLOYING HEATING PROCESS
14 
 
Figure 2: Schematic representation of the processes involved in the preparation of ODTs by employing heat based 
technology. 
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TECHNOLOGIES EMPLOYING WITHOUT HEATING PROCESS
14
 
 
Figure 3: Schematic representation of the process involved in the different methods for preparation of ODTs without using 
heating process. 
6) FLASHTAB TECHNOLOGY: 
Prographarm laboratories have patented the Flashtab 
technology. This technology involves the preparation of 
rapidly disintegrating tablet which consists of an active 
ingredient in the form of microcrystal. Drug microgranules 
may be prepared by using the conventional techniques like 
coacervation, extrusion-spheronization, simple pan coating 
methods and microencapsulation. The microcrystal of 
microgranules of the active ingredient is added to the 
granulated mixture of excipients prepared by wet or dry 
granulation, and compressed into tablets. All the processing 
utilized the conventional tableting technology, and the tablets 
produced are reported to have good mechanical strength and 
disintegration time less than one minute. 
7) ORAQUICK TECHNOLOGY: 
OraQuick utilizes its own patented taste masking technology 
i.e. MicroMask®. In MicroMask® technology, taste masking 
process is done by incorporating drug into matrix 
microsphere. In this technique, tablet is prepared by 
dissolving the sugar (sucrose, mannitol, sorbitol, xylose, 
dextrose, fructose or mannose) and protein (albumin or 
gelatine) in a suitable solvent such as water, ethanol, 
isopropyl alcohol and ethanol-water mixture. The solution of 
matrix is then spray dried, yielding highly porous granules. 
Also, utilization of lower heat of production is advantageous 
for heat-sensitive drugs. Granules formed then mixed with 
drug and other excipients and compressed at low compression 
force. KV pharmaceuticals claimed that matrix formed 
protects and surrounds the drug powder in microencapsulated 
particles is more reliable during this step. 
 
8) QUICK –DIS TECHNOLOGY: 
Lavipharm has invented an ideal intra-oral mouth dissolving 
drug delivery system, which satisfies the unmet needs of the 
market. The novel intra-oral drug delivery system, 
trademarked Quick-Dis™, is Lavipharm‟s proprietary 
patented technology and is a thin, flexible, and quick-
dissolving film. The film is placed on the top or the floor of 
the tongue. It is retained at the site of application and rapidly 
releases the active agent for local and/or systemic absorption. 
The typical disintegration time is only 5 to 10 seconds for the 
Quick-Dis™ film with a thickness of 2 mm.                    
 
9) NANOCRYSTAL TECHNOLOGY: 
 For orally disintegrating tablets, Elan's proprietary 
Nanocrystal technology can enable formulation and improve 
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compound activity and final product characteristics. 
Decreasing particle size increases the surface area, which 
leads to an increase in dissolution rate. This can be 
accomplished predictably and efficiently using Nanocrystal 
technology. Nanocrystal particles are small particles of drug 
substance, typically less than 1000 nm in diameter, which are 
produced by milling the drug substance using a proprietary 
wet milling technique. Nanocrystal colloidal dispersions of 
drug substance are combined with water-soluble ingredients, 
filled into blisters, and lyophilized. The resultant wafers are 
remarkably robust, yet dissolve in very small quantities of 
water in seconds. 
 
INTRODUCTION TO MOTION SICKNESS
19 - 24
 
DEFNITION:    
Motion sickness is the uncomfortable dizziness, nausea, and 
vomiting that people experience when their sense of balance 
and equilibrium is disturbed by constant motion. Riding in a 
car, aboard a ship or boat, or riding on a swing all cause 
stimulation of the vestibular system and visual stimulation 
that often leads to discomfort. 
DESCRIPTION: 
Motion sickness is a common problem, with nearly 80 percent 
of the general population suffering from it at one time in their 
lives. People with migraine headaches or grave's syndrome, 
however, are more likely than others to have recurrent 
episodes of motion sickness. Researchers at the Naval 
Medical Center in San Diego, California, reported in 2003 
that 70 percent of research subjects were suffering from 
severe motion sickness which had abnormalities of the 
vestibular system. 
While motion sickness may occur at any age, it is more 
common in children over the age of two, with the majority 
outgrowing this susceptibility. 
When looking at why motion sickness occurs, it is helpful to 
understand the role of the sensory organs. The sensory organs 
control a body's sense of balance by telling the brain what 
direction the body is pointing, the direction it is moving, and 
if it is standing still or turning. These messages are relayed by 
the inner ears (or labyrinth); the eyes; the skin pressure 
receptors, such as in those in the feet; the muscle and joint 
sensory receptors, which track what body parts are moving; 
and the central nervous system (the brain and spinal cord), 
which is responsible for processing all incoming sensory 
information. 
Motion sickness and its symptoms surface when conflicting 
messages are sent to the central nervous system. An example 
of this is reading a book in the back seat of a moving car. The 
inner ears and skin receptors sense the motion, but the eyes 
register only the stationary pages of the book. This conflicting 
information may cause the usual motion sickness symptoms 
of dizziness, nausea and vomiting.
 
CAUSES AND SYMPTOMS: 
While all five of the body's sensory organs contribute to 
motion sickness, excess stimulation to the vestibular system 
within the inner ear (the body's "balance center") has been 
shown to be one of the primary reasons for this condition. 
Balance problems, or vertigo, are caused by a conflict 
between what is seen and how the inner ear perceives it, 
leading to confusion in the brain. This confusion may result in 
higher heart rates, rapid breathing, nausea and sweating, along 
with dizziness and vomiting. 
Pure optokinetic motion sickness is caused solely by visual 
stimuli, or what is seen. The optokinetic system is the reflex 
that allows the eyes to move when an object moves. Many 
people suffer when what they view is rotating or swaying, 
even if they are standing still. 
Additional factors that may contribute to the occurrence of 
motion sickness include: 
 Poor ventilation.  
 Anxiety or fear. Both have been found to lower a person's 
threshold for experiencing motion sickness symptoms.  
 Heavy meal of spicy and greasy foods be avoided before 
and during a trip.  
 Alcohol. A drink is often thought to help calm the nerves, 
but in this case it could upset the stomach further. A 
hangover for the next morning's trip may also lead to 
motion sickness.  
 Genetic factors. Research suggests that some people inherit 
a predisposition to motion sickness. This predisposition is 
more marked in some ethnic groups than in others; one 
study published in 2002 found that persons of Chinese or 
Japanese ancestry are significantly more vulnerable to 
motion sickness than persons of British ancestry.  
 Pregnancy. Susceptibility in women to vomiting during 
pregnancy appears to be related to motion sickness, 
although the precise connections are not well understood. 
DIAGNOSIS: 
Most cases of motion sickness are mild and self-treatable 
disorders. If symptoms such as dizziness become chronic, a 
doctor may be able to help alleviate the discomfort by looking 
further into a patient's general health. Questions regarding 
medications, head injuries, recent infections, and other 
questions about the ear and neurological system will be asked. 
An examination of the ears, nose, and throat, as well as tests 
of nerve and balance function, may also be completed. Severe 
cases of motion sickness symptoms, and those that become 
progressively worse, may require additional, specific tests. 
Diagnosis in these situations deserves the attention and care 
of a doctor with specialized skills in diseases of the ear, nose, 
throat, equilibrium, and neurological system. 
TREATMENT OF MOTION SICKNESS: 
Most medications for motion sickness need to be taken at 
least 30 minutes before exposure to the activity that can cause 
the problem. Persons with glaucoma or prostate problems 
should not take most of these medications unless so advised 
by their doctor. 
 Antihistamines  
 Cinnarizine, Meclizine of the antihistamine family can 
cause drowsiness like other most other medications, it is 
best to take these before motion stimulation.  
 Dimenhydrinate (Dramamine). Similar to meclizine. 
Liquid forms are available. 
 Cyclizine is similar to meclizine. It is suitable for children 
6 years of age or older as well as adults.  
 Haldol, Thorazine -- these anti-psychotic drugs have 
dopamine blocking activity which is useful for blocking 
nausea as well as stimulating stomach motion which helps 
clear food from the digestive tract.  
 Promethazine. This drug is one of the most effective 
available for motion sickness. One dose lasts up to 8 
hours. Like the other drugs, it can cause drowsiness. 
 PHYSICO-MECHANICAL PARAMETERS 
 Bulk Density
11 
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Weighed quantity of Cinnarizine was transferred into 100 ml 
measuring cylinder without tapping during transfer. The 
volume occupied by drug was measured. Bulk density was 
measured by using formula 
ρi   = m /Vi 
                    Where, m   = mass of the blend 
             Vi   = untapped volume 
Tapped density
12
  
Weighed quantity of drug was taken into a graduated cylinder. 
Volume occupied by the drug was noted down. Then the 
cylinder was subjected to 500, 750 &1250 taps in tap density 
apparatus. 
ρt = m/Vt 
Where, Vt = tapped volume 
                    m = mass of the blend 
 Carr’s Index (Compressibility)
13
  
The compressibility index and Hausner ratio are measures of 
the property of powder to be compressed. The packing ability 
of drug was evaluated from change in volume, which is due to 
rearrangement of packing occurring during tapping. It was 
indicated as Carr’s compressibility index was calculated as 
follows. 
Carr’s index = [Tapped density - Bulk density/Tapped 
density] X 100 
Hausner Ratio
13
  
It is measurement of frictional resistance of the drug .The 
ideal range should be 1.2-1.5. It was determined by the ratio 
of tapped density and bulk density 
Hausner Ratio = Tapped density / Bulk density 
 Angle of Repose:
14 
Weighed quantity of the drug was passed through a funnel 
kept at a height 2 cm from the base. The powder was passed 
till it forms a heap and touches the tip of the funnel. The 
radius was measured and angle of repose was calculated by 
using above formula. It is defined as the maximum angle that 
can be obtained between the free standing of powder heap and 
horizontal plane, which is given by the equation:
 
                                                       = tan
-1 h
/r 
Where,     = Angle of repose 
              h   = Height of powder heap,   
 r   = Radius of the powder cone. 
SELECTION OF EXCIPIENTS: 
Following excipients were selected to fulfill the criteria of fast 
disintegrating tablet. 
(a) PVP k-30:  
In tableting, povidone solutions are used as binders in wet 
granulation processes. It was also aid in disintegration and 
dissolution. Povidone is used as a solubilizer in oral and 
parenteral formulations and has been shown to enhance 
dissolution of poorly soluble drugs from solid-dosage forms. 
(b) Microcrystalline Cellulose (Avicel 102):  
It is widely used as a diluent in tablets and capsules. It is used 
in both wet granulation and direct compression processes and 
also used as tablet disintegrant. It has both binding and 
disintegrant action. 
(c) Crosscarmellose Sodium: 
It swells 4-8 folds in 10 seconds. The cellulose derivative 
swells in two dimensions radially. In tablet formulations, 
croscarmellose sodium may be used in both direct 
compression and wet granulation processes. When used in 
wet granulation croscarmellose sodium is added to in both the 
wet and dry stages of the process so that wicking and swelling 
ability can both be utilized. 
(d) Sodium Starch Glycolate: 
Sodium starch glycolate is widely used in oral 
pharmaceuticals as a disintegrant in tablet and capsule 
formulations. It is commonly used in tablets prepared by 
either direct compression or wet granulation process. The 
usual concentration employed in a formulation is between 2-
8%. Disintegration occurs by rapid uptake of water followed 
by rapid and enormous swelling. 
(e) Sodium Bicarbonate (NaHCO3):  
Carbon dioxide generating agents like sodium hydrogen 
carbonate (NaHCO3), it swells in the gastric fluid as it gets 
contact with the aqueous medium. Formation of CO2 and 
entrapment of that gas into the polymeric gel causes swelling 
of the dosage form resulting a bulk density less than 1. It then 
remains buoyant and floats in the gastric fluid, resulting a 
prolonged gastric residence time 
(f) Mannitol: 
As a Diluent in tablets (10-90% w/w). It is not hygroscopic 
and used with moisture sensitive active ingredients. Mannitol 
is commonly use as an excipient in the manufacture of 
chewable tablet and mouth dissolving formulation because of 
its negative heat of solution, sweetness and mouth feel. 
(g) Talc:  
Talc is also used as a lubricant in tablet formulations; in a 
novel powder coating for extended-release pellets; and as an 
adsorbant. However, it is widely used as a dissolution 
retardant in the development of controlled-release products.  
(h) Lactose:  
Lactose is widely used as filler or diluents in tablets and 
capsules, and to a more limited extent in lyophilized products 
and infant formula. 
(i) Magnesium stearate: 
Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture at concentrations 
between 0.25% to 5.0% w/w. 
DRUG EXCIPIENT INTERACTION STUDY 
The Drug -Excipients study was carried out by physical 
mixing and observations were recorded as a change in the 
colour. 
Study Methods:- 
(a) Cinnarizine + Diluents (1:5) Ratio:- 
About 0.1 gm of Cinnarizine + 0.5 gm of Diluents were 
weighed accurately in a tarred Petri dish. Mixture was heated 
in oven at 30
0
, 40
0
, 50
0
, 60
0
 C different temperatures & 75% 
relative humidity and color changed was observed at these 
temperatures. 
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(b) Cinnarizine. + Binder (1:5) Ratio:-  
About 0.1 gm of Cinnarizine + 0.5 gm Binder were weighed 
accurately in a tarred Petri dish and heated in oven at different 
temperature. Color changed was observed at these 
temperatures. 
(c) Cinnarizine + Lubricants (20:1) Ratio:-  
About 0.2 gm of Cinnarizine + 0.01 gm of Lubricants were 
weighed accurately in a tarred Petri dish and heated in oven at 
different temperature. Color changed was observed at these 
temperatures. 
(d) Cinnarizine + Superdisintegrants (1:1):- 
About 0.1 gm of Cinnarizine + 0.1 gm of Superdisintegrants 
were weighed accurately in a tarred Petri dish and heated in 
oven at different temperature. Color changed was observed at 
these temperatures. 
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